Patients with HIV who immediately started antiretroviral therapy significantly reduced the risk of spreading the virus to an uninfected partner, compared with those who delayed therapy, according to results of a multinational study. The study also found that antiretroviral therapy reduced the risk of transmission by 96%.
A recent Food and Drug Administration inspection prompted the recall of dietary supplements distributed by Multi-Mex Distributor, the company announced Monday. According to an FDA post, the supplements in question bore a close resemblance to antibiotics available in Mexico and may have been confusing to Hispanic consumers.
The seventh annual Armada Specialty Pharmacy Summit, convened at The Wynn resort and casino this week, attracted nearly 1,500 attendees — a rise of almost 50% over 2010 — and about 80 exhibiting companies.
Pharmacy benefit manager Medco’s research arm is teaming up with personalized medicine and pharmacogenetics company AssureRx Health in a pilot program to evaluate adherence and medical care utilization among patients taking antidepressants and antipsychotics.
Nordic Naturals is attempting to crack the mass channel code with an initial 200-store test with Walgreens, the company told Drug Store News. Nordic boasts a strong heritage across the specialty channel.
Cobalis on Tuesday began airing 60-second television commercials in support of its PreHistin allergy defense formula across national cable and satellite networks as part of a planned $5 million spend, the company announced.
Patients with moderate to severe rheumatoid arthritis who respond to 12 weeks of treatment with a drug made by UCB are more likely to show improvement in their condition in the long run, according to results of a study published in the Journal of Rheumatology.
The Food and Drug Administration will expedite its review of an investigational drug made by Bayer HealthCare Pharmaceuticals for treating tumors of the gastrointestinal tract, the company said Tuesday.
The Food and Drug Administration is moving forward in the creation of a regulatory approval pathway for follow-on biologics and is requesting input from stakeholders and the public, the agency said Monday.
Drug maker Merck announced that it has kicked off an initiative that includes a wide range of public education and patient support programs, as well as research efforts to help improve care for people living with chronic hepatitis C virus infections.